SEC filing · 10-K

Nanoviricides, Inc.: Annual report

NanoViricides reported a reduced net loss for fiscal year 2026 but raised substantial doubt about its ability to continue as a going concern.

Filed September 28, 2026 · period ended June 30, 2026

Negative for the company

What the numbers say

Diluted EPS -$0.41 versus -$0.63; operating cash flow -$7.7M (a year earlier -$8.5M); free cash flow -$7.8M (a year earlier -$8.5M); cash rose by $1.2M to $2.8M; diluted share count up 34% (dilution).

Compared with the same period a year earlier, from the figures Nanoviricides, Inc. reported to the SEC.

What happened

The company generated no revenue and recorded a net loss of approximately $8,219,000 for the fiscal year ended June 30, 2026.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Nanoviricides, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.